Li Wanjun, chairman of Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd., Jiang Pan, deputy general manager, and Wei Pingzhi, project manager, visited Chutian Huatong on August 6th and served as the R&D center of Chutian Huatong Zhifeilongkoma Industrial Park The executive team of the project and the New Crown Vaccine Project awarded Chutian Huatong the honorary titles of "Excellent Technical Team" and "Excellent Supplier", and awarded Chutian Huatong employees Jiang Haiyang and Cai Fuqiang "Excellent Project Manager" and "Excellent Construction Manager" "Honorary title," at the same time as a gift to Chutian Huatong Chairman Yang Wenlu and employees Jiang Haiyang and Cai Fuqiang "Zhifei Biological 100 million doses" commemorative silver coins.

Chutian Huatong Chairman Yang Wenlu led the heads of Chutian Huatong's R&D, production, and engineering departments to hold a forum with Li Wanjun, Chairman of Zhifeilong Kema and his party. Li Wanjun fully affirmed Chutian Huatong’s technical R&D, manufacturing and engineering capabilities, and highly praised Chutian Huatong’s high-quality, high-standard, and high-efficiency project delivery for its contribution to the large-scale production of Zhifeilongkema's new crown vaccine, and We express our full recognition and trust to the Chutian Huatong project team, "We hope that Chutian Huatong will continue to exert team strength in the next new crown vaccine stock solution project, overcome difficulties, and promote the smooth delivery of the project. Chutian Huatong joined hands to make greater contributions to the fight against the new crown epidemic."

In 2020, Chutian Huatong and Zhifeilongkoma will launch an important cooperation on the industrial park R&D center project. In 2021, Chutian Huatong and Zhifeilongkema will produce the original solution water system, distribution system, and inactivation system of the new crown vaccine on a large scale. The project has launched important cooperation. Chutian Huatong attaches great importance to the production and delivery of the project. Chairman Yang Wenlu personally deploys and follows up the progress of the important nodes of the project. The project team abides by Chutian’s “customer-centric, struggling-oriented, and goal-oriented” project. The business tenet of “responsibility and result-oriented” promotes project production and delivery with close teamwork and strong execution, which creates important value for customers and is highly recognized.

Chutian Huatong Chairman Yang Wenlu led the heads of relevant departments to accompany Zhifeilongkema Chairman Li Wanjun and his entourage for in-depth inspections, and conducted in-depth exchanges on Zhifeilongkema's new crown vaccine related projects. Anhui Zhifei Longkoma Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. It is a high-tech enterprise integrating R&D, production and sales of biological products. It is mainly engaged in immune preparations, vaccines, and genetic recombination. The R&D and production business of biological products such as products serves public health and is committed to realizing the grand vision of "biological dreams, healthy dreams, Chinese dreams, and Zhifei dreams".

In January 2020, Zhifeilongkoma cooperated with the Institute of Microbiology of the Chinese Academy of Sciences to jointly develop and reorganize the subunit COVID-19 vaccine. This project was included in the national emergency special-key research and development plan "Public Security Risk Prevention and Control and Emergency Technology and Equipment" key special project , The team went all out to develop a recombinant protein vaccine for the new coronavirus and achieved major research results. In June of that year, it officially entered clinical trials and became China's first recombinant protein vaccine to enter the clinical stage. Zhifeilong Kema raced against the new crown vaccine development and production on the road, demonstrating the Chinese speed and power of the new crown vaccine, and made important contributions to the world's fight against the new crown epidemic.